Physician profile
Erika Young
NPI 1750363206
$13,295.23
in general payments reported to CMS, 2019-2025
26 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $464 · 2021: $957 · 2022: $1,499 · 2023: $6,010 · 2024: $1,069 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Food and Beverage: $4,402 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Food and Beverage | $4,401.77 |
| Education | $101.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $5,440.52 | 2021-2025 | Vibativ |
| Viiv Healthcare Company | $1,968.83 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $899.03 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $762.29 | 2019-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Abbvie INC. | $743.53 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Paratek Pharmaceuticals, INC. | $686.60 | 2019-2025 | Nuzyra |
| Insmed, INC. | $550.55 | 2019-2025 | Arikayce, Brinsupri |
| Shionogi INC | $447.45 | 2022-2025 | Fetroja |
| Astellas Pharma US INC | $305.29 | 2019-2023 | Cresemba |
| Allergan, INC. | $303.89 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $248.81 | 2020-2025 | Xerava, Zevtera, Xacduro |
| Melinta Therapeutics, LLC | $247.29 | 2023-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Boston Scientific Corporation | $92.70 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $90.58 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $83.43 | 2020-2025 | |
| Emd Serono, INC. | $65.23 | 2024-2025 | |
| Janssen Biotech, INC. | $56.07 | 2022-2023 | Symtuza |
| Theratechnologies INC. | $45.96 | 2020-2024 | Trogarzo, Egrifta |
| Ferring Pharmaceuticals INC. | $20.78 | 2025 | Rebyota |
| Napo Pharmaceuticals INC | $20.42 | 2019 | |
| Csl Behring | $20.32 | 2025 | Hizentra |
| Vyera Pharmaceuticals, LLC | $19.21 | 2022 | |
| Pfizer INC. | $18.22 | 2025 | |
| Shire North American Group INC | $17.58 | 2019 | |
| Aimmune Therapeutics, INC. | $15.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.